Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy
Conclusions:
Our results show that outcomes in HER2+ patients with early BC not receiving anti-HER2 therapy strongly depend on HR expression. The very high early risk of relapse seen in HER2 + HR- patients is particularly relevant in health care settings with limited access to adjuvant anti-HER2 treatment. The event rates shown for subpopulations of HER2+ BC patients suggest that in resource-constrained environments patients with HER2 + HR- early BC should be prioritized for consideration of adjuvant anti-HER2 therapy. (Source: Breast Cancer Research)
Source: Breast Cancer Research - April 16, 2015 Category: Cancer & Oncology Authors: Kathrin Strasser-WeipplNora HorickIan SmithJoyce O¿ShaughnessyBent EjlertsenFrances BoyleAman BuzdarPierre FumoleauWilliam GradisharMiguel MartinBeverly MoyMartine Piccart-GebhartKathleen PritchardDeborah LindquistErica RappoldDianne FinkelsteinPaul Goss Source Type: research
Long non-coding RNA expression profiles predict metastasis in lymph node-negative breast cancer independently of traditional prognostic markers
Conclusions:
To our knowledge, this is the first study investigating the prognostic potential of lncRNA profiles. Our study suggest that lncRNA profiles provide additional prognostic information and may contribute to the identification of early breast cancer patients eligible for adjuvant therapy, as well as early breast cancer patients that could avoid unnecessary systemic adjuvant therapy. This study emphasizes the potential role of lncRNAs in breast cancer prognosis. (Source: Breast Cancer Research)
Source: Breast Cancer Research - April 11, 2015 Category: Cancer & Oncology Authors: Kristina SørensenMads ThomassenQihua TanMartin BakSøren ColdMark BurtonMartin LarsenTorben Kruse Source Type: research
The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy
No description available (Source: Breast Cancer Research)
Source: Breast Cancer Research - April 10, 2015 Category: Cancer & Oncology Authors: François BertucciPascal FinettiDaniel Birnbaum Source Type: research
Quantification of HER family receptors in breast cancer
The clinical success of trastuzumab in breast cancer taught us that appropriate tumor evaluation is mandatory for the correct identification of patients eligible for targeted therapies. Although HER2 protein expression by immunohistochemistry (IHC) and gene amplification by fluorescence in situ hybridization (FISH) assays are routinely used to select patients to receive trastuzumab, both assays only partially predict response to the drug. In the case of epidermal growth factor receptor (EGFR), the link between the presence of the receptor or its amplification and response to anti-EGFR therapies could not be demonstrated. E...
Source: Breast Cancer Research - April 9, 2015 Category: Cancer & Oncology Authors: Paolo NuciforoNina Radosevic-RobinTony NgMaurizio Scaltriti Source Type: research
Targeting PTEN-defined breast cancers with a one-two punch
With tremendous advances in sequencing and analysis in recent years, a wealth of genetic information has become available to identify and classify breast cancer into five main subtypes - luminal A, luminal B, claudin-low, human epidermal growth factor receptor 2-enriched, and basal-like. Current treatment decisions are often based on these classifications, and while more beneficial than any single treatment for all breast cancers, targeted therapeutics have exhibited limited success with most of the subtypes. Luminal B breast cancers are associated with early relapse following endocrine therapy and often exhibit a poor pro...
Source: Breast Cancer Research - April 8, 2015 Category: Cancer & Oncology Authors: Leonard MaggiJason Weber Source Type: research
The clinical and functional significance of c-Met in breast cancer: a review
c-Met is a receptor tyrosine kinase that upon binding of its ligand, hepatocyte growth factor (HGF), activates downstream pathways with diverse cellular functions that are important in organ development and cancer progression. Anomalous c-Met signalling has been described in a variety of cancer types, and the receptor is regarded as a novel therapeutic target. In breast cancer there is a need to develop new treatments, particularly for the aggressive subtypes such as triple-negative and basal-like cancer, which currently lack targeted therapy. Over the last two decades, much has been learnt about the functional role of c-M...
Source: Breast Cancer Research - April 8, 2015 Category: Cancer & Oncology Authors: Colan Ho-YenJ JonesStephanie Kermorgant Source Type: research
Background risk of breast cancer and the association between physical activity and mammographic density
IntroductionHigh physical activity has been shown to decrease the risk of breast cancer, potentially by a mechanism that also reduces mammographic density. We tested the hypothesis that the risk of developing breast cancer in the next 10 years according to the Tyrer-Cuzick prediction model influences the association between physical activity and mammographic density.
Methods:
We conducted a population-based cross-sectional study of 38,913 Swedish women aged 40–74 years. Physical activity was assessed using the validated web-questionnaire Active-Q and mammographic density was measured by the fully automated volumetric Vol...
Source: Breast Cancer Research - April 2, 2015 Category: Cancer & Oncology Authors: Thang TrinhMikael ErikssonHatef DarabiStephanie BonnJudith BrandJack CuzickKamila CzeneArvid SjölanderKatarina BälterPer Hall Source Type: research
Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study
IntroductionThe relationship between circulating prolactin and invasive breast cancer has been investigated previously, but the association between prolactin levels and in situ breast cancer risk has received less attention.
Methods:
We analysed the relationship between pre-diagnostic prolactin levels and the risk of in situ breast cancer overall, and by menopausal status and use of postmenopausal hormone therapy (HT) at blood donation. Conditional logistic regression was used to assess this association in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, inc...
Source: Breast Cancer Research - March 31, 2015 Category: Cancer & Oncology Authors: Kaja TikkDisorn SookthaiRenée FortnerTheron JohnsonSabina RinaldiIsabelle RomieuAnne TjønnelandAnja OlsenKim OvervadFrançoise Clavel-ChapelonLaura BagliettoHeiner BoeingAntonia TrichopoulouPagona LagiouDimitrios TrichopoulosGiovanna MasalaVittorio Krog Source Type: research
Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D,L-lactic-co-glycolic) acid nanoparticles nanoparticles
Conclusion:
Taken together these findings demonstrate that the delivery of the immunostimulatory peptide Hp91 inside PLGA-NPs enhances the potency of the peptide and efficacy of a breast cancer vaccine. (Source: Breast Cancer Research)
Source: Breast Cancer Research - March 31, 2015 Category: Cancer & Oncology Authors: Diahnn CampbellRebecca SaenzIla BharatiDaniel SeibleLiangfang ZhangSadik EsenerBradley MessmerMarie LarssonDavorka Messmer Source Type: research
FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth
Conclusions:
FAK signaling occurs in the nucleolus, active FAK protects NS, and Akt-mTOR pathway regulates NS protein stability needed for breast carcinoma spheroid and tumor growth. (Source: Breast Cancer Research)
Source: Breast Cancer Research - March 28, 2015 Category: Cancer & Oncology Authors: Isabelle TancioniNichol MillerSean UryuChristine LawsonChristine JeanXiao ChenElizabeth KleinschmidtDavid Schlaepfer Source Type: research
Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases
Conclusions:
Our results demonstrate that the liver-metastatic potential of breast cancer cells is heavily reliant on interactions with infiltrating Ly-6G+ cells within the liver microenvironment. (Source: Breast Cancer Research)
Source: Breast Cancer Research - March 27, 2015 Category: Cancer & Oncology Authors: Sébastien TabarièsVéronique OuelletBrian HsuMatthew AnnisApril RoseLiliane MeunierEuridice CarmonaChristine TamAnne-Marie Mes-MassonPeter Siegel Source Type: research
Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy
Conclusions:
We show that podocalyxin plays a key role in the formation of primary tumors and distant tumor metastasis. In addition, we validate podocalyxin as potential target for monoclonal antibody therapy to inhibit primary tumor growth and systemic dissemination. (Source: Breast Cancer Research)
Source: Breast Cancer Research - March 27, 2015 Category: Cancer & Oncology Authors: Kimberly SnyderMichael HughesBradley HedbergJill BrandonDiana HernaezPeter BergqvistFrederic CruzKelvin PoMarcia GravesMichelle TurveyJulie NielsenJohn WilkinsShaun McCollJohn BabcookCalvin RoskelleyKelly McNagny Source Type: research
Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF
Conclusions:
This study indicates that genetic and phenotypic variation of both TFPIα and TFPIβ, more than TF, are markers of cancer progression. Together with the previously demonstrated tumor suppressor effects of TFPI, the beneficial effect of tumor expressed TFPI on survival, renders TFPI as a potential anticancer agent, and the clinical significance of TFPI in cancer deserves further investigation. (Source: Breast Cancer Research)
Source: Breast Cancer Research - March 26, 2015 Category: Cancer & Oncology Authors: Mari TinholtHans VollanKristine SahlbergSandra JernströmFatemeh KavehOle LingjærdeRolf KåresenTorill SauerVessela KristensenAnne-Lise Børresen-DalePer SandsetNina Iversen Source Type: research
Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a pre-clinical model
Conclusions:
Our findings demonstrate that the IBC clinical phenotype is promoted by signaling from the microenvironment perhaps in addition to tumor cell drivers. (Source: Breast Cancer Research)
Source: Breast Cancer Research - March 20, 2015 Category: Cancer & Oncology Authors: Lara LacerdaBisrat DebebDaniel SmithRichard LarsonTravis SolleyWei XuSavitri KrishnamurthyYun GongLawrence LevyThomas BuchholzNaoto UenoAnn KloppWendy Woodward Source Type: research
Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response
IntroductionTriple-negative (TN) breast cancers need to be refined in order to identify therapeutic subgroups of patients.
Methods:
We conducted an unsupervised analysis of microarray gene-expression profiles of 107 TN breast cancer patients and undertook robust functional annotation of the molecular entities found by means of numerous approaches including immunohistochemistry and gene-expression signatures. An 87 TN external cohort was used for validation.
Results:
Fuzzy clustering separated TN tumours into three clusters: C1 (22.4%), C2 (44.9%) and C3 (32.7%). C1 patients were older (mean = 64.6 years) than C2 (mean...
Source: Breast Cancer Research - March 20, 2015 Category: Cancer & Oncology Authors: Pascal JézéquelDelphine LoussouarnCatherine Guérin-CharbonnelLoïc CampionAntoine VanierWilfried GouraudHamza LaslaCatherine GuetteIsabelle ValoVéronique VerrièleMario Campone Source Type: research
